BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7881348)

  • 1. Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias.
    Gandhi V; Huang P; Plunkett W
    Leuk Lymphoma; 1994; 14 Suppl 2():3-9. PubMed ID: 7881348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular and clinical pharmacology of fludarabine.
    Gandhi V; Plunkett W
    Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
    Iwasaki H; Huang P; Keating MJ; Plunkett W
    Blood; 1997 Jul; 90(1):270-8. PubMed ID: 9207462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine for treatment of adult acute myelogenous leukemia.
    Gandhi V
    Leuk Lymphoma; 1993; 11 Suppl 2():7-13. PubMed ID: 8124234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of fludarabine in hematological malignancies.
    Montillo M; Ricci F; Tedeschi A
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1141-61. PubMed ID: 17020450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
    Gandhi V; Plunkett W; Weller S; Du M; Ayres M; Rodriguez CO; Ramakrishna P; Rosner GL; Hodge JP; O'Brien S; Keating MJ
    J Clin Oncol; 2001 Apr; 19(8):2142-52. PubMed ID: 11304766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and action of fludarabine phosphate.
    Plunkett W; Huang P; Gandhi V
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):3-17. PubMed ID: 1699280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
    Yamamoto S; Yamauchi T; Kawai Y; Takemura H; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Int J Hematol; 2007 Feb; 85(2):108-15. PubMed ID: 17321987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical modulation of arabinosylcytosine for therapy of leukemias.
    Gandhi V; Estey E; Keating MJ; Plunkett W
    Leuk Lymphoma; 1993; 10 Suppl():109-14. PubMed ID: 8481660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF; Huang P; Plunkett W; Gandhi V
    Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
    Kemena A; Gandhi V; Shewach DS; Keating M; Plunkett W
    Cancer Chemother Pharmacol; 1992; 31(3):193-9. PubMed ID: 1464155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of novel plasmid constructs to demonstrate fludarabine triphosphate inhibition of nucleotide excision repair of a site-specific 1,2-d(GpG) intrastrand cisplatin adduct.
    Li MJ; Yang LY
    Int J Oncol; 1999 Dec; 15(6):1177-83. PubMed ID: 10568825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of fludarabine and arabinosylcytosine on multidrug resistant cells.
    Michelutti A; Michieli M; Damiani D; Melli C; Ermacora A; Grimaz S; Candoni A; Russo D; Fanin R; Baccarani M
    Haematologica; 1997; 82(2):143-7. PubMed ID: 9175315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
    Gandhi V; Kemena A; Keating MJ; Plunkett W
    Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.
    Yamauchi T; Nowak BJ; Keating MJ; Plunkett W
    Clin Cancer Res; 2001 Nov; 7(11):3580-9. PubMed ID: 11705880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of the arabinosides and the pharmacology of fludarabine.
    Plunkett W; Gandhi V
    Drugs; 1994; 47 Suppl 6():30-8. PubMed ID: 7525187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells.
    White EL; Shaddix SC; Brockman RW; Bennett LL
    Cancer Res; 1982 Jun; 42(6):2260-4. PubMed ID: 7042080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
    Gandhi V; Estey E; Keating MJ; Plunkett W
    J Clin Oncol; 1993 Jan; 11(1):116-24. PubMed ID: 8418222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.